Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells
Katrine Frønsdal1, Fahri Saatcioglu
1Department of Molecular Biosciences, University of Oslo, Oslo, Norway.
Background:
Histone deacetylase (HDAC) inhibitors have shown significant anti-proliferative and apoptotic properties on various cancer cells, including prostate cancer, and are therefore being evaluated as treatment modalities. However, the specific effect of HDAC inhibitors on androgen-sensitive and androgen-independent cell lines have not been thoroughly studied which we hypothesized could be different. We therefore assessed whether three structurally unrelated HDAC inhibitors, trichostatin A (TSA), depsipeptide (FR901228), and sodium butyrate, affect cell death in the prostate cancer cell lines LNCaP, DU-145, and PC-3.
Methods:
To investigate the extent and the nature of cell death, we used Trypan blue exclusion assay, phase-contrast light microscopy, fluorescence microscopy, and Western blot analyses.
Results:
At concentrations where they potentiate transcriptional activation, all three HDAC inhibitors induced cell death in LNCaP and DU-145 cells, but not in PC-3 cells, within the timeline of the experiments. HDAC inhibitor-induced cell death in LNCaP and DU-145 cells showed several characteristic apoptotic features, such as cell shrinkage, nuclear condensation, and poly(ADP) ribose polymerase cleavage. However, there were differences in the way LNCaP and DU-145 cells responded to treatment with various HDAC inhibitors. For example, whereas TSA and FR901228 were more effective in inducing apoptosis in LNCaP cells compared with DU-145 cells, the reverse was true for sodium butyrate. Moreover, within the same cell line, TSA, FR901228, and sodium butyrate exhibited different potencies for induction of apoptosis.
Conclusions:
Collectively, these results suggest that the response of prostate cancer cells to HDAC inhibitors is not uniform, but cell line and inhibitor specific. Given that prostate cancer is generally a multiclonal disease representing different cell lineages, it is important to develop HDAC inhibitors that will be effective against all of these cell types.
Insights
Histone deacetylase (HDAC) inhibitors show anti-cancer effects, but prostate cancer cell responses vary by cell line and inhibitor type. Further research is needed to develop effective HDAC inhibitors for all prostate cancer cell types.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Histone deacetylase (HDAC) inhibitors are investigated for their anti-proliferative and apoptotic effects in cancer treatment.
- The differential effects of HDAC inhibitors on androgen-sensitive versus androgen-independent prostate cancer cells require further investigation.
Purpose of the Study:
- To assess the impact of three structurally distinct HDAC inhibitors (trichostatin A, depsipeptide, and sodium butyrate) on cell death in LNCaP, DU-145, and PC-3 prostate cancer cell lines.
Main Methods:
- Cell death was evaluated using Trypan blue exclusion, phase-contrast and fluorescence microscopy, and Western blot analyses.
- Apoptotic features such as cell shrinkage, nuclear condensation, and PARP cleavage were assessed.
Main Results:
- All tested HDAC inhibitors induced cell death in LNCaP and DU-145 cells but not PC-3 cells.
- HDAC inhibitor-induced cell death exhibited apoptotic characteristics in sensitive cell lines.
- Differential efficacy and potency were observed among the inhibitors and cell lines, indicating specific responses.
Conclusions:
- Prostate cancer cell response to HDAC inhibitors is heterogeneous, varying by cell line and specific drug.
- Developing HDAC inhibitors effective against diverse prostate cancer cell types is crucial for multiclonal disease treatment.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:30Apoptosis
01:24Caspases
01:17The Extrinsic Apoptotic Pathway
01:31The Intrinsic Apoptotic Pathway
01:20The JAK-STAT Signaling Pathway